XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.3
Stock-Based Compensation
6 Months Ended
Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation

8. Stock-Based Compensation

 

The Company recorded stock-based compensation expense in the following categories on the accompanying condensed consolidated statements of operations for the periods presented (in thousands):

 

         
   Three Months Ended June 30, 
   2024   2023 
Cost of revenue  $4   $- 
General and administrative   92    116 
Sales and marketing   2    - 
Research and development   5    164 
Total stock-based compensation expense  $103   $280 

 

         
   Six Months Ended June 30, 
   2024   2023 
Cost of revenue  $8   $- 
General and administrative   220    232 
Sales and marketing   3    - 
Research and development   9    416 
Total stock-based compensation expense  $240   $648 

 

Equity incentive plan – summary

 

During 2023, the Company adopted the OneMedNet Corporation 2022 Equity Incentive Plan (the “2022 Plan”) and reserved an amount of shares of Common Stock equal to 10% of the number of shares of Common Stock of the Company following the Business Combination for issuance thereunder. The 2022 Plan became effective immediately upon the closing of the Business Combination and replaced the Legacy ONMD equity incentive plan.

 

Equity incentive plan – stock options

 

For the three months ended June 30, 2024 and 2023, the Company recorded stock-based compensation expense of $0 and $132 thousand, respectively, on its outstanding stock options.

 

For the six months ended June 30, 2024 and 2023, the Company recorded stock-based compensation expense of $34 thousand and $264 thousand, respectively, on its outstanding stock options.

 

Equity incentive plan – restricted stock units (“RSU”)

 

For the three months ended June 30, 2024 and 2023, the Company recorded stock-based compensation expense of $103 thousand and $148 thousand, respectively, on its outstanding restricted stock units.

 

For the six months ended June 30, 2024 and 2023, the Company recorded stock-based compensation expense of $206 thousand and $384 thousand, respectively, on its outstanding restricted stock units.